Drawing for ROCKET ISOTOPES

USPTO serial 79456199

ROCKET ISOTOPES

Reviewed by CopyMark Law Group

Status 641Office Action
Filing date
Status date
Registration date
—
Examiner
PRIZANT, JAMES
Law office
TMO LAW OFFICE 135

What this means

The USPTO has issued an Office Action on this application. A response is typically required before the deadline, or the application can be abandoned.

Status 641: Status 641 means the USPTO mailed a non-final Office Action identifying issues with your application. You typically have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.

Need help with ROCKET ISOTOPES?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Get help with this Office Action, set up monitoring, or talk with CopyMark.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.

Owner

Goods and services

ClassDescriptionStatusFirst use
001Chemical preparations and substances for manufacturing pharmaceutical products, in particular radiopharmaceutical products.ACTIVE—
005Pharmaceutical products, medical and veterinary preparations; pharmaceutical products, substances and preparations, in particular for prevention and treatment of diseases, including cancers; substances and preparations for medical use; pharmaceutical products for medical use for diagnosis; pharmaceutical preparations and compositions for cancer prevention and treatment; radiopharmaceutical products.ACTIVE—
035Retail or wholesale services for pharmaceutical, veterinary and sanitary preparations as well as for medical supplies; retail sale services for pharmaceutical, veterinary and sanitary preparations as well as medical supplies; wholesale services for pharmaceutical, veterinary and sanitary preparations as well as medical supplies; retail or wholesale services relating to medicines, including generic medicines, medical apparatus and instruments.ACTIVE—
042Pharmaceutical research and development services; research and development in the fields of nuclear medicine, radionuclides and radiopharmaceutical products; scientific research and development of radionuclides and radiopharmaceuticals, in particular concerning methods for producing and manufacturing radionuclides and radiopharmaceuticals, particularly for radionuclides and radiopharmaceuticals of pharmaceutical quality; preparation of scientific reports; provision of medical and scientific research information in the field of pharmaceutical products, in particular radiopharmaceutical products; advice in relation to all the aforementioned services.ACTIVE—
044Medical and pharmaceutical services; medical and pharmaceutical consultant services; preparation of medical and pharmaceutical expert reports in connection with the treatment of persons; provision of medical information in the field of cancer prevention, screening, diagnosis and treatment; advice in relation to all the aforementioned services.ACTIVE—

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

DateCodeEventWhat it means
Nov 12, 2026RFNTREFUSAL PROCESSED BY IB—
Oct 24, 2026RFCSNON-FINAL ACTION MAILED - REFUSAL SENT TO IB—
Oct 24, 2026RFRRREFUSAL PROCESSED BY MPU—
Oct 15, 2026NREPNEW REPRESENTATIVE AT IB RECEIVED—
Aug 18, 2026RFCRNON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW—
Aug 17, 2026CNRTNON-FINAL ACTION WRITTENA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Aug 17, 2026DOCKASSIGNED TO EXAMINER—
Aug 16, 2026MAFRAPPLICATION FILING RECEIPT MAILED—
Aug 16, 2026NWOSNEW APPLICATION OFFICE SUPPLIED DATA ENTERED—
Aug 13, 2026REPRSN ASSIGNED FOR SECT 66A APPL FROM IB—

Frequently asked questions

Related guidance